Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 214

Similar articles for PubMed (Select 15094138)

1.

OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.

Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M.

Osteoarthritis Cartilage. 2004 May;12(5):389-99.

2.

Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria.

Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M; OMERACT-OARSI.

J Rheumatol. 2003 Jul;30(7):1648-54. Review.

PMID:
12858473
3.
4.

The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI.

Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, Torrance GW, Tugwell P, Polisson R.

Osteoarthritis Cartilage. 2005 Feb;13(2):104-10.

5.
6.

Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.

Bingham CO 3rd, Bird SR, Smugar SS, Xu X, Tershakovec AM.

Osteoarthritis Cartilage. 2008 Nov;16(11):1289-93. doi: 10.1016/j.joca.2008.04.009. Epub 2008 Jun 2.

7.

OARSI/OMERACT criteria of being considered a candidate for total joint replacement in knee/hip osteoarthritis as an endpoint in clinical trials evaluating potential disease modifying osteoarthritic drugs.

Dougados M, Hawker G, Lohmander S, Davis AM, Dieppe P, Maillefert JF, Gossec L.

J Rheumatol. 2009 Sep;36(9):2097-9. doi: 10.3899/jrheum.090365.

PMID:
19738220
8.

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.

Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS.

Clin Rheumatol. 2006 Feb;25(1):42-53. Epub 2005 Aug 13.

PMID:
16132165
9.

Patient acceptable symptom state and OMERACT-OARSI set of responder criteria in joint replacement. Identification of cut-off values.

Escobar A, Gonzalez M, Quintana JM, Vrotsou K, Bilbao A, Herrera-EspiƱeira C, Garcia-Perez L, Aizpuru F, Sarasqueta C.

Osteoarthritis Cartilage. 2012 Feb;20(2):87-92. doi: 10.1016/j.joca.2011.11.007. Epub 2011 Nov 20.

10.

A comparison of the OARSI response criteria with patient's global assessment in patients with osteoarthritis of the hip treated with a non-pharmacological intervention.

Hoeksma HL, van den Ende CH, Breedveld FC, Ronday HK, Dekker J.

Osteoarthritis Cartilage. 2006 Jan;14(1):77-81. Epub 2005 Oct 7.

11.

Clinical response to intra-articular injections of hylan G-F 20 in symptomatic hip osteoarthritis: the OMERACT-OARSI criteria applied to the results of a pilot study.

Conrozier T, Bertin P, Bailleul F, Mathieu P, Charlot J, Vignon E, Treves R, Chevalier X.

Joint Bone Spine. 2006 Dec;73(6):705-9. Epub 2006 Aug 30.

PMID:
16997602
12.

OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis.

Ornetti P, Brandt K, Hellio-Le Graverand MP, Hochberg M, Hunter DJ, Kloppenburg M, Lane N, Maillefert JF, Mazzuca SA, Spector T, Utard-Wlerick G, Vignon E, Dougados M.

Osteoarthritis Cartilage. 2009 Jul;17(7):856-63. doi: 10.1016/j.joca.2009.01.007. Epub 2009 Feb 9. Review.

13.

Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis.

Hochberg MC, Wohlreich M, Gaynor P, Hanna S, Risser R.

J Rheumatol. 2012 Feb;39(2):352-8. doi: 10.3899/jrheum.110307. Epub 2011 Dec 1.

PMID:
22133624
14.
15.

Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.

Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY; Group for the Respect of Excellence and Ethics in Science.

Osteoarthritis Cartilage. 2004 Apr;12(4):263-8. Review.

16.

OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis.

Gossec L, Hawker G, Davis AM, Maillefert JF, Lohmander LS, Altman R, Cibere J, Conaghan PG, Hochberg MC, Jordan JM, Katz JN, March L, Mahomed N, Pavelka K, Roos EM, Suarez-Almazor ME, Zanoli G, Dougados M.

J Rheumatol. 2007 Jun;34(6):1432-5.

PMID:
17552070
17.

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P.

Osteoarthritis Cartilage. 2008 Feb;16(2):137-62. doi: 10.1016/j.joca.2007.12.013. Review.

18.

Comparing two low-energy diets for the treatment of knee osteoarthritis symptoms in obese patients: a pragmatic randomized clinical trial.

Riecke BF, Christensen R, Christensen P, Leeds AR, Boesen M, Lohmander LS, Astrup A, Bliddal H.

Osteoarthritis Cartilage. 2010 Jun;18(6):746-54. doi: 10.1016/j.joca.2010.02.012. Epub 2010 Feb 17.

19.

Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.

Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, Litschig S, Sloan VS.

Curr Med Res Opin. 2005 Apr;21(4):517-26.

PMID:
15899100
20.

The treatment and prevention of knee osteoarthritis: a tool for clinical decision-making.

Bliddal H, Christensen R.

Expert Opin Pharmacother. 2009 Aug;10(11):1793-804. doi: 10.1517/14656560903018911. Review.

PMID:
19537998
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk